Faculty

Adam Omelianchuk, PhD, MA, HEC-C
Assistant Professor, Medical Ethics
Baylor College of Medicine;
Practicing Clinical Ethicist
Houston Methodist Hospital

Brendan Parent, JD
Associate Professor, Department of Population Health
Associate Professor, Department of Surgery
NYU Grossman School of Medicine

Brendan Parent, JD, is associate professor and director of transplant ethics and policy research in the division of medical ethics with joint appointment in surgery at NYU Grossman School of Medicine. He is a principal investigator leading multimillion-dollar NIH- and nonprofit-funded grants studying ethics and regulation of transplant research. Parent also serves as an independent living-donor advocate, an advisory board member for the National Kidney Foundation, and a member of the national leadership council for The Organ Donation and Transplantation Alliance. He provides ethics consultation for transplant programs across the globe. Parent’s current work also focuses on ethics challenges surrounding determination of death by neurologic criteria, research on the deceased, and artificial intelligence in health research. He has published academic articles in peer-reviewed journals spanning law, medicine, science, sports, and ethics, and his work has been featured in the Washington Post, The New York Times, Wired, Chicago Tribune, The Guardian, and on NPR. 

Adam Omelianchuk, PhD, MA, HEC-C, is an assistant professor at Baylor College of Medicine’s Center for Medical Ethics and Health Policy and practicing clinical ethicist consultant at Houston Methodist Hospital. He served as an Observer for the Uniform Law Commission’s Determination of Death Act Committe from 2021 to 2023 and chaired the IRB at AnMed Health Medical Center in Anderson, SC from 2019 to 2020. During the pandemic years, he completed a clinical ethics fellowship at the Stanford Center for Biomedical Ethics and Stanford Health Care where he developed his expertise in the biological and social validity of “brain death” declarations and the ethical validity of the “dead-donor rule” in organ transplantation. His work has appeared Neurology, Hastings Center Report, and the American Journal for Bioethics. 

Planners
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education

Sarah Chart, RN
Vice President
Optum Health Education

Sara Fleszar, PharmD, BCOP
Senior Clinical Pharmacist
Optum Health Solutions

Rebecca Gleason, RN, CCM
Activity Manager
Optum Health Education

Lisa Latts, MD, MSPH, MBA, FACP
Chief Medical Officer
Optum Behavioral Health Solutions & Optum Health Solutions
Optum Health Clinical Excellence
Optum

Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Optum Health Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

Financial Relationship Key
 A-Advisory Board
 CT-Clinical Trial
 C-Consultant
 E-Employee
 G- Grant/Research Support or Funding
 I-Stocks and Other Ownership Interests 
 S-Speakers’ Bureau
 O-Other Financial or Material Support

Brendan Parent, JD: ProcureOnDemand, Bexorg (A); United Therapeutics (G)

All relevant financial relationships have been mitigated. 

The remaining faculty and planners have no financial relationships to disclose.